Investigating immune interactions in lung cancer
Official title: Project 1: Delta immune Ecology of NSCLC
Funded at H. Lee Moffitt Cancer Ctr & Res Inst · NIH-10930171 · Data updated 2026-11-12
This study is looking at how tumors in non-small cell lung cancer with KRAS mutations interact with the immune system, so we can find out which patients might respond best to immunotherapy and create more personalized treatment plans just for them.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | H. Lee Moffitt Cancer Ctr & Res Inst NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $475,697 |
| NIH project number | 5U54CA274507-02 |
| Project ID | NIH-10930171 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with KRAS-mutant non-small cell lung cancer who are undergoing immunotherapy.
✕Less likely to help
Patients with non-KRAS-mutant lung cancers or those not receiving immunotherapy may not benefit from this research.
What this research studies
This research focuses on understanding how tumors interact with the immune system in non-small cell lung cancer (NSCLC), particularly in cases with KRAS mutations. By analyzing pre-treatment and on-treatment biopsies, the study aims to identify unique immune patterns that can predict how well patients will respond to immunotherapy. Advanced computational techniques will be used to analyze the spatial relationships between tumor cells and immune cells, potentially leading to more effective treatment strategies. The goal is to develop biomarkers that can guide personalized therapy based on individual tumor-immune interactions.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for lung cancer patients, enhancing their response to therapies.
How similar studies have gone: Previous research has shown promise in understanding tumor-immune interactions, but this approach is innovative and aims to provide new insights into treatment responses.
Where this research is happening
-
H. Lee Moffitt Cancer Ctr & Res Inst
Tampa, United States Active
Researchers
- Principal investigator: Anderson, Alexander Robertson Allan — H. Lee Moffitt Cancer Ctr & Res Inst
- Study coordinator: Anderson, Alexander Robertson Allan
Related research
Other NIH-funded projects on the same topics.
-
7-marker protein test to predict NSCLC response to anti-PD-1 therapy
A Johns Hopkins team is testing a 7-marker protein test to help predict which advanced NSCLC patients will respond to anti-PD-1 therapy.
-
Barcoded tumor sequencing to map radiation-triggered immune effects in lung cancer
This project uses barcoded tumor models and sequencing to uncover how adding radiation to immunotherapy might spark whole-body immune attacks against non-small cell lung cancer.
-
Targeting the cancer-friendly secretory system in a common lung cancer cancer subtype
A study tests new ways to block the secretory system inside tumor cells to stop growth and spread in a major subtype of non-small cell lung cancer.
-
Predicting outcomes and side effects in stage III NSCLC with AI-driven imaging
A multimodal AI approach uses chest CT and tissue images to forecast how patients with unresectable stage III NSCLC will respond to durvalumab after chemoradiotherapy and who might develop pneumonitis.
-
ATM kinase as a target to help NSCLC with brain metastases respond to treatment
A study from Yale University tests whether blocking ATM kinase can delay or overcome treatment resistance in people with advanced non-small cell lung cancer that has spread to the brain and other organs.
-
Understanding how cancer-supportive tissue affects resistance to ALK and KRAS therapies
A research team will study how the tumor’s surrounding tissue changes as cancer cells become resistant to ALK and KRAS-targeted treatments, aiming to find better combination strategies for long-lasting remission.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.